332 related articles for article (PubMed ID: 8851847)
1. [Effect of biological prognostic factors on therapy of non-seminomatous stage I testicular tumors--an assessment of the current status].
Kuczyk MA; Bokemeyer C; Serth J; Machtens S; Höfner K; Jonas U
Urologe A; 1996 Jan; 35(1):35-45. PubMed ID: 8851847
[TBL] [Abstract][Full Text] [Related]
2. Nonseminomatous germ cell testicular tumors clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only.
Ondrus D; Ondrusova M; Hornak M; Matoska J
Neoplasma; 2007; 54(5):437-42. PubMed ID: 17688374
[TBL] [Abstract][Full Text] [Related]
3. Evolution of the management of stage I nonseminomatous germ-cell tumors of the testis.
Sogani PC
Urol Clin North Am; 1991 Aug; 18(3):561-73. PubMed ID: 1652171
[TBL] [Abstract][Full Text] [Related]
4. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis.
Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW
Cancer; 1998 Sep; 83(5):1002-11. PubMed ID: 9731905
[TBL] [Abstract][Full Text] [Related]
5. Surgical aspects in the treatment of patients with testicular cancer.
Richie JP
Hematol Oncol Clin North Am; 1991 Dec; 5(6):1127-42. PubMed ID: 1663937
[TBL] [Abstract][Full Text] [Related]
6. [Urologic treatment of testicular germ cell cancer].
Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
[TBL] [Abstract][Full Text] [Related]
7. Management of patients with clinical stage I nonseminomatous testicular germ cell tumours: active surveillance versus primary chemotherapy versus nerve sparing retroperitoneal lymphadenectomy.
Heidenreich A; Pfister D
Arch Esp Urol; 2012 Mar; 65(2):215-26. PubMed ID: 22414450
[TBL] [Abstract][Full Text] [Related]
8. [New parameters for prediction of pathological stage in clinical stage I non-seminomatous testicular tumors].
Albers P; Ulbright TM; Albers J; Miller GA; Foster RS; Donohue JP
Urologe A; 1995 Jul; 34(4):316-23. PubMed ID: 7676541
[TBL] [Abstract][Full Text] [Related]
9. [Risk-guided after-care of testicular tumor].
Schölermann KH; Dettmann R; Hartmann M
Urologe A; 1996 Jul; 35(4):326-30. PubMed ID: 8928363
[TBL] [Abstract][Full Text] [Related]
10. The management of stage I nonseminomatous testicular germ cell tumors.
Pectasides D; Farmakis D; Pectasides M
Oncology; 2006; 71(3-4):151-8. PubMed ID: 17646698
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
12. Current management of stage I testicular non-seminomatous germ cell tumours.
Pectasides D; Pectasides E; Constantinidou A; Aravantinos G
Crit Rev Oncol Hematol; 2009 May; 70(2):114-23. PubMed ID: 18805019
[TBL] [Abstract][Full Text] [Related]
13. [Modified retroperitoneal lymphadenectomy in non-seminomatous stage I, IIa and IIb testicular tumors].
Sparwasser C; Treiber U; Beckert R; Pust RA
Urologe A; 1995 Nov; 34(6):444-8. PubMed ID: 8848854
[TBL] [Abstract][Full Text] [Related]
14. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.
Stephenson AJ; Bosl GJ; Bajorin DF; Stasi J; Motzer RJ; Sheinfeld J
J Urol; 2005 Aug; 174(2):557-60; discussion 560. PubMed ID: 16006891
[TBL] [Abstract][Full Text] [Related]
15. [Results of the German studies (MAHO) for treatment of testicular germ cell tumors in children--an update].
Schmidt P; Haas RJ; Göbel U; Calaminus G
Klin Padiatr; 2002; 214(4):167-72. PubMed ID: 12165897
[TBL] [Abstract][Full Text] [Related]
16. [Delayed retroperitoneal lymph node excision in treatment of advanced non-seminomatous germinal cell tumors. I. Intraoperative findings in marker converted tumor].
Otto T; Goepel M; Seeber S; Rübben H
Urologe A; 1993 May; 32(3):189-93. PubMed ID: 7685554
[TBL] [Abstract][Full Text] [Related]
17. [Therapy of testicular germ cell tumors. Current status of the MAHO studies].
Haas RJ; Schmidt P; Göbel U; Harms D
Klin Padiatr; 1993; 205(4):225-30. PubMed ID: 8397320
[TBL] [Abstract][Full Text] [Related]
18. Surgical management of low-stage nonseminomatous germ cell testicular cancer.
Stephenson AJ; Klein EA
BJU Int; 2009 Nov; 104(9 Pt B):1362-8. PubMed ID: 19840014
[TBL] [Abstract][Full Text] [Related]
19. Retroperitoneal lymph node dissection in patients with high risk testicular cancer.
Williams SB; McDermott DW; Dock W; Bahnson E; Berry AM; Steele GS; Richie JP
J Urol; 2009 May; 181(5):2097-101; discussion 2101-2. PubMed ID: 19286227
[TBL] [Abstract][Full Text] [Related]
20. [Is lymphadenectomy in stage I of non-seminomatous testicular cancer still justified?].
Höltl W; Kosak D; Pont J; Hruby W
Wien Klin Wochenschr; 1987 Jan; 99(2):60-3. PubMed ID: 3564488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
